Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults with Nonalcoholic Fatty Liver Disease

Overview

Journal Clin Gastroenterol Hepatol

Specialty Gastroenterology

Date 2014 May 22

PMID 24846279

Citations 48

Authors

Raj Vuppalanchi

Ajay K Jain

Ross Deppe

Katherine Yates

Megan Comerford

Howard C Masuoka

Brent A Neuschwander-Tetri

Rohit Loomba

Elizabeth M Brunt

David E Kleiner

Jean P Molleston

Jeffrey B Schwimmer

Joel E Lavine

James Tonascia

Naga Chalasani

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Cross-sectional studies have associated serum levels of the keratin 18 (K18) fragment with histologic features of liver in individuals with nonalcoholic fatty liver disease (NAFLD). We investigated the relationship between changes in serum levels of K18 and changes in liver histology in adults and children with NAFLD.

Methods: We measured levels of K18 in stored serum samples collected at baseline and various time points from 231 adults with nonalcoholic steatohepatitis and 152 children with NAFLD who participated in 2 separate prospective randomized clinical trials. Liver biopsy specimens collected at baseline and week 96 were reviewed centrally.

Results: There were greater decreases in serum levels of K18 in adults with histologic improvement at week 96 than in those without histologic improvement at week 16 (decrease, 193 ± 293 vs 139 ± 467 U/L; P < .001), week 48 (decrease, 232 ± 360 vs 113 ± 425 U/L; P < .001), or week 96 (decrease, 269 ± 368 vs 97 ± 400 U/L; P < .001). There were greater decreases in serum levels of K18 in children with histologic improvements than in those without histologic improvements at week 48 (decrease, 197 ± 467 vs 47 ± 350 U/L; P = .005) and week 96 (decrease, 206 ± 432 vs 2 ± 474 U/L; P < .001). However, reductions in serum levels of K18 were not better than reductions in levels of alanine aminotransferase in identifying adults with histologic improvement (area under the receiver operator characteristic [AUROC], 0.71; 95% confidence interval [CI], 0.63-0.80; vs AUROC, 0.68; 95% CI, 0.61-0.79; P = .34) or children (AUROC, 0.72; 95% CI, 0.63-0.81; vs AUROC, 0.79; 95% CI, 0.70-0.87; P = .42).

Conclusions: Decreases in serum levels of K18 are associated strongly with improved liver histologies in adults or children with NAFLD. However, reductions in K18 do not perform better than those in alanine aminotransferase level in identifying histologic changes in NAFLD.

Citing Articles

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal A, Kaplan L, Frias J, Brouwers B, Wu Q, Thomas M Nat Med. 2024; 30(7):2037-2048.

PMID: 38858523 PMC: 11271400. DOI: 10.1038/s41591-024-03018-2.

Association between BMI Change, Transaminases, and Other Metabolic Parameters in Children with Nonalcoholic Fatty Liver Disease.

Flores Lopez A, Quiros-Tejeira R, Lyden E, McGill B, Dike C J Obes. 2024; 2024:6997280.

PMID: 38817395 PMC: 11139528. DOI: 10.1155/2024/6997280.

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.

Gilca-Blanariu G, Budur D, Mitrica D, Gologan E, Timofte O, Balan G Metabolites. 2023; 13(11).

PMID: 37999211 PMC: 10672868. DOI: 10.3390/metabo13111115.

Biomarkers of Hepatic Dysfunction and Cardiovascular Risk.

Lee Jr T, Kueh M, Jain V, Razavi A, Alebna P, Chew N Curr Cardiol Rep. 2023; 25(12):1783-1795.

PMID: 37971635 PMC: 10902719. DOI: 10.1007/s11886-023-01993-5.

Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article.

El-Eshmawy M Porto Biomed J. 2023; 8(5):e228.

PMID: 37846300 PMC: 10575409. DOI: 10.1097/j.pbj.0000000000000228.

References

Farrell G, Wong V, Chitturi S . NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307-18. DOI: 10.1038/nrgastro.2013.34. View

Ascha M, Hanouneh I, Lopez R, Tamimi T, Feldstein A, Zein N . The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6):1972-8. DOI: 10.1002/hep.23527. View

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View

Bellentani S, Scaglioni F, Marino M, Bedogni G . Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28(1):155-61. DOI: 10.1159/000282080. View

Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

Canbay A, Feldstein A, Higuchi H, Werneburg N, Grambihler A, Bronk S . Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003; 38(5):1188-98. DOI: 10.1053/jhep.2003.50472. View

Shen J, Chan H, Wong G, Choi P, Chan A, Chan H . Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012; 56(6):1363-70. DOI: 10.1016/j.jhep.2011.12.025. View

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107(6):811-26. DOI: 10.1038/ajg.2012.128. View

Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B . Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2013; 60(1):167-74. DOI: 10.1016/j.jhep.2013.07.042. View

10.

Chalasani N, Sanyal A, Kowdley K, Robuck P, Hoofnagle J, Kleiner D . Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2008; 30(1):88-96. PMC: 2929909. DOI: 10.1016/j.cct.2008.09.003. View

11.

Gupta R, Bhangoo A, Matthews N, Anhalt H, Matta Y, Lamichhane B . The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Pediatr Endocrinol Metab. 2012; 24(11-12):907-11. DOI: 10.1515/jpem.2011.282. View

12.

Szczepaniak L, Nurenberg P, Leonard D, Browning J, Reingold J, Grundy S . Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2004; 288(2):E462-8. DOI: 10.1152/ajpendo.00064.2004. View

13.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

14.

Feldstein A, Wieckowska A, Lopez A, Liu Y, Zein N, McCullough A . Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009; 50(4):1072-8. PMC: 2757511. DOI: 10.1002/hep.23050. View

15.

Neuschwander-Tetri B, Clark J, Bass N, Van Natta M, Unalp-Arida A, Tonascia J . Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52(3):913-24. PMC: 3070295. DOI: 10.1002/hep.23784. View

16.

Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M . Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol. 2010; 44(6):440-7. DOI: 10.1097/MCG.0b013e3181bdefe2. View

17.

Cui J . Estimating AIDS incidence and jack-knife variance from a continuous delay distribution and incomplete data. Stat Med. 1999; 18(5):527-37. DOI: 10.1002/(sici)1097-0258(19990315)18:5<527::aid-sim54>3.0.co;2-l. View

18.

Kwok R, Tse Y, Wong G, Ha Y, Lee A, Ngu M . Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2013; 39(3):254-69. DOI: 10.1111/apt.12569. View

19.

Lavine J, Schwimmer J, Van Natta M, Molleston J, Murray K, Rosenthal P . Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16):1659-68. PMC: 3110082. DOI: 10.1001/jama.2011.520. View

20.

Feldstein A, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V . Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013; 108(9):1526-31. DOI: 10.1038/ajg.2013.168. View